| 11.4246 0.275 (2.46%) | 04-14 13:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.77 | 1-year : | 14.76 |
| Resists | First : | 11.79 | Second : | 12.64 |
| Pivot price | 11.48 |
|||
| Supports | First : | 10.41 | Second : | 8.66 |
| MAs | MA(5) : | 11.76  |
MA(20) : | 11.39 |
| MA(100) : | 16.38 |
MA(250) : | 15.38 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 55.4 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 22.54 | Low : | 10.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KROS ] has closed above bottom band by 46.9%. Bollinger Bands are 34.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.35 - 11.42 | 11.42 - 11.47 |
| Low: | 10.62 - 10.71 | 10.71 - 10.78 |
| Close: | 11.03 - 11.16 | 11.16 - 11.26 |
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Sun, 12 Apr 2026
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Tue, 07 Apr 2026
BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics - Stock Titan
Tue, 07 Apr 2026
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Mon, 06 Apr 2026
Keros Therapeutics (KROS) CEO exercises options for 55,000 shares - Stock Titan
Mon, 06 Apr 2026
JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Fri, 27 Mar 2026
Vanguard disaggregates holdings; reports 0 KROS shares (KROS) - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 1.917e+007 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 2,380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 7.208e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 35.6 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 576.6 % |
| Return on Equity (ttm) | 9.2 % |
| Qtrly Rev. Growth | 2.4406e+008 % |
| Gross Profit (p.s.) | -97 |
| Sales Per Share | 22.11 |
| EBITDA (p.s.) | 1.29911e+008 |
| Qtrly Earnings Growth | 2.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 108 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.51 |
| Price to Cash Flow | 0.66 |
| Dividend | 0 |
| Forward Dividend | 1.99e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|